Sep 11, 2019 / 05:00PM GMT
David Reed Risinger - Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst
All right. Good afternoon, everyone. So I'm pleased to welcome one of the executive team members of Eli Lilly, Dan Skovronsky, who is the Head of R&D, effectively. His formal title is Chief Scientific Officer and President of Lilly Research Laboratories. Dan, we're happy to have you here. I do need to refer everyone to a disclaimer at www.morganstanley.com/researchdisclosures.
Just to give you a little bit of a sense for Dan's background. He interestingly has responsibility for Global Business Development at Lilly, which is new for the Head of R&D at Lilly, and I'll ask you talk about that a little bit. And he originally joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals where he had been CEO since founding the company in 2004.
So Dan, you've been Chief Scientific Officer since last summer. I would love to hear a little bit about how you're evolving
Eli Lilly and Co at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers